Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: Paying homage to the podocyte

被引:63
作者
Hayden, MR
Whaley-Connell, A
Sowers, JR
机构
[1] Univ Missouri, Dept Internal Med,Sch Med, Div Endocrinol Diabet & Metab, Diabet & Cardiovasc Dis Ctr,Hlth Sci Ctr, Columbia, MO 65212 USA
[2] Univ Missouri, Dept Physiol & Pharmacol, Sch Med, Columbia, MO 65212 USA
关键词
asymmetrical dimethylarginine; atherosclerosis; cardiorenal metabolic syndrome; glomerulosclerosis; microalbuminuria; NAD(P)H oxidase; oxidative stress; podocyte; reactive oxygen species;
D O I
10.1159/000088810
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes mellitus has reached epidemic proportions and diabetic nephropathy is the leading cause of end-stage renal disease. The metabolic syndrome constitutes a milieu conducive to tissue redox stress. This loss of redox homeostasis contributes to renal remodeling and parallels the concurrent increased vascular redox stress associated with the cardiometabolic syndrome. The multiple metabolic toxicities, redox stress and endothelial dysfunction combine to weave the complicated mosaic fabric of diabetic glomerulosclerosis and diabetic nephropathy. A better understanding may provide both the clinician and researcher tools to unravel this complicated disease process. Cellular remodeling of podocyte foot processes in the Ren-2 transgenic rat model of tissue angiotensin II overexpression (TG(mREN-2) 27) and the Zucker diabetic fatty model of type 2 diabetes mellitus have been observed in preliminary studies. Importantly, angiotensin II receptor blockers have been shown to abrogate these ultrastructural changes in the foot processes of the podocyte in preliminary studies. An integrated, global risk reduction, approach in therapy addressing the multiple metabolic abnormalities combined with attempts to reach therapeutic goals at an earlier stage could have a profound effect on the development and progressive nature to end-stage renal disease and ultimately renal replacement therapy. Copyright (C) 2005 S. Karger AG, Basel.
引用
收藏
页码:553 / 569
页数:17
相关论文
共 130 条
[61]  
JENNINGS PE, 1987, DIABETES RES CLIN EX, V6, P151
[62]   Activation of extracellular matrix metalloproteinases in equine laminitis [J].
Johnson, PJ ;
Tyagi, SC ;
Katwa, LC ;
Ganjam, VK ;
Moore, LA ;
Kreeger, JM ;
Messer, NT .
VETERINARY RECORD, 1998, 142 (15) :392-396
[63]   β-cell neogenesis in type 2 diabetes [J].
Jones, LC ;
Clark, A .
DIABETES, 2001, 50 :S186-S187
[64]   Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk [J].
Kailasam, MT ;
Parmer, RJ ;
Tyrell, EA ;
Henry, RR ;
O'Connor, DT .
JOURNAL OF HYPERTENSION, 2000, 18 (11) :1611-1620
[65]   Supplementation with tetrahydrobiopterin prevents the cardiovascular effects of angiotensin II-induced oxidative and nitrosative stress [J].
Kase, H ;
Hashikabe, Y ;
Uchida, K ;
Nakanishi, N ;
Hattori, Y .
JOURNAL OF HYPERTENSION, 2005, 23 (07) :1375-1382
[66]  
KEANE WF, 1995, KIDNEY INT, V56, P1
[67]   ACE and non-ACE pathways in the renal vascular response to RAS interruption in type 1 diabetes mellitus [J].
Lansang, MC ;
Stevanovic, R ;
Price, DA ;
Laffel, LMB ;
Hollenberg, NK .
KIDNEY INTERNATIONAL, 2005, 67 (03) :1033-1037
[68]   Effect of high glucose on superoxide in human mesangial cells: Role of angiotensin [J].
Leehey, DJ ;
Isreb, MA ;
Marcic, S ;
Singh, AK ;
Singh, R .
NEPHRON EXPERIMENTAL NEPHROLOGY, 2005, 100 (01) :E46-E53
[69]   Very low-density lipoprotein stimulates the expression of monocyte chemoattractant protein-1 in mesangial cells [J].
Lynn, EG ;
Siow, YL ;
O, K .
KIDNEY INTERNATIONAL, 2000, 57 (04) :1472-1483
[70]   Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy [J].
Maeda, S ;
Haneda, M ;
Guo, BL ;
Koya, D ;
Hayashi, K ;
Sugimoto, T ;
Isshiki, K ;
Yasuda, H ;
Kashiwagi, A ;
Kikkawa, R .
KIDNEY INTERNATIONAL, 2001, 60 (04) :1428-1434